The experiment by Daniele Cretella et al. suggests that even in the case of resistance to EGFR-TKIs, T-DM1 may provide a new therapeutic strategy for NSCLC with HER2 overexpression (Cretella et al., 2014). Here, ERBB2 is linked to non-small cell lung carcinoma.